MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2022 International Congress

    Choice of shoulder muscles for the multi-pattern treatment of upper limb spasticity with botulinum neurotoxin injections

    J. Jacinto (Alcabideche, Portugal)

    Objective: To present an experts’ consensus on the use of botulinum neurotoxin (BoNT) injections in the multi-pattern treatment of shoulder spasticity to increase awareness of…
  • 2022 International Congress

    Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis

    F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck (Munich, Germany)

    Objective: To present pooled data analyses of the immunogenicity of incobotulinumtoxinA (INCO) in pediatrics. Background: BotulinumtoxinA (BoNT-A) is used to treat several chronic pediatric conditions,…
  • 2022 International Congress

    Pain and Disability Outcomes in Hemiparetic Patients With Post-Stroke Spasticity: Exploratory Analysis of the ASPIRE Study

    G. Bavikatte, G. Francisco, W. Jost, A. Barichich, E. Duarte, M. Schwartz, T. Musacchio, A. Esquenazi (Liverpool, United Kingdom)

    Objective: To assess measures of pain and functional impairment in hemiparetic patients with post-stroke spasticity (PSS) treated with onabotulinumtoxinA (onabotA) from the Adult Spasticity International…
  • 2022 International Congress

    Treating Upper Limb Spasticity With OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns From the ASPIRE Study

    G. Francisco, W. Feng, M. Munin, K. Ngo, M. Schwartz, M. Sadeghi, A. Zuzek, A. Esquenazi (Houston, USA)

    Objective: To examine onabotulinumtoxinA (onabotA) treatment utilization patterns in the United States (US) for pronated forearm and intrinsic plus hand postures in patients with upper…
  • MDS Virtual Congress 2021

    OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study

    G. Bavikatte, G. Francisco, A. Esquenazi, M. Dimyan, K. Ngo, M. Schwartz, A. Zuzek, W. Jost (Liverpool, United Kingdom)

    Objective: Examine onabotulinumtoxinA utilization in patients with upper limb (UL) and lower limb (LL) spasticity from the Adult Spasticity International Registry (ASPIRE) study to gain…
  • MDS Virtual Congress 2021

    Assessing effectiveness of abobotulinumtoxinA injections for adult lower limb spasticity in routine clinical practice: The ongoing AboLiSh study

    A. Esquenazi, R. Zorowitz, S. Ashford, F. Calvi-Gries, P. Maisonobe, S. Page, J. Jacinto (Elkins Park, USA)

    Objective: The aim of this ongoing observational study is to systematically assess goal attainment over 16 months in patients treated with ≥1 abobotulinumtoxinA (aboBoNT-A) injection(s)…
  • MDS Virtual Congress 2021

    Absence of neutralizing antibody formation during incobotulinumtoxinA treatment of spasticity in botulinum toxin-naïve children with cerebral palsy: pooled analysis of Phase 3 studies

    H. Chambers, P. Kaňovský, A. Schroeder, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira, F. Heinen (San Diego, USA)

    Objective: To investigate neutralizing antibody (NAb) formation in three large Phase 3 studies with incobotulinumtoxinA, a botulinum neurotoxin type A (BoNT-A) with no complexing proteins,…
  • MDS Virtual Congress 2021

    Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children/adolescents with cerebral palsy: the XARA study

    E. Dabrowski, H. Chambers, D. Gaebler-Spira, M. Banach, P. Kaňovský, A. Hanschmann, M. Althaus, T. Geister, F. Heinen (Royal Oak, USA)

    Objective: To assess the efficacy/safety of incobotulinumtoxinA for upper- and combined upper-/lower-limb spasticity in ambulant and non-ambulant children/adolescents with cerebral palsy (CP). Background: Spastic CP…
  • MDS Virtual Congress 2021

    A phase IV, randomized, double-blind cross-over study comparing the clinical safety, efficacy and duration of abobotulinumtoxinA with onabotulinumtoxinA in adults with upper-limb spasticity: The DIRECTION study

    A. Esquenazi, Z. Ayyoub, M. Verduzco-Gutierrez, P. Maisonobe, J. Otto, A. Patel (Elkins Park, USA)

    Objective: To evaluate the safety and efficacy of abobotulinumtoxinA in comparison to onabotulinumtoxinA when used at optimized doses in approved muscles common to both products’…
  • MDS Virtual Congress 2021

    Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies

    F. Heinen, P. Kaňovský, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira (Munich, Germany)

    Objective: To assess the effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies. Background: In children/adolescents with…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley